<DOC>
	<DOCNO>NCT00980551</DOCNO>
	<brief_summary>The investigator test subtenon carboplatin combination vincristine topotecan give vein hop find drug combination may effective retinoblastoma come back ( recurrent ) resistant treatment ( refractory ) . The goal study : - To decide drug combination useful treatment recurrent refractory retinoblastoma - To test safety drug combination see kind effect ( good bad ) expect drug combination - To measure visual change study therapy - To use special MRI scan measure brain function involve vision processing , study therapy In study , investigator also test new experimental way give carboplatin `` subtenon carboplatin '' . The carboplatin give directly eye needle place cover eye . This try get carboplatin retinoblastoma inside eye .</brief_summary>
	<brief_title>Pilot Study Topotecan/Vincristine With Subconjunctival Carboplatin Patients With Bilateral Retinoblastoma</brief_title>
	<detailed_description />
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age : ≤ 10 year age Diagnosis : Patients must history bilateral Retinoblastoma AND Recurrent/Refractory IntraOcular Retinoblastoma consider amenable cure local therapy alone ( photocoagulation argon laser , cryotherapy , transpupillary thermotherapy , radioactive plaque therapy ) . Therapeutic Options : Patient 's disease status one know option proven provide high chance ocular salvage cure external beam radiation enucleation . Remaining visual function target eye ( ) require Life Expectancy &gt; 8 week Lansky ≥ 50 Prior Therapy : Patients must local relapsed/refractory disease receive standard upfront therapy involve least one chemotherapeutic regimen . There limit prior chemotherapeutic regimen permit . Patients may receive previous intravenous carboplatin , may receive prior subtenon carboplatin intravenous topotecan . Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study , describe : Myelosuppressive chemotherapy : patient must receive myelosuppressive chemotherapy within 3 week study enrollment Biologic therapy : Patients must receive biologic anticancer agent within one week study enrollment Radiation therapy : Four week must elapse since external beam radiation therapy , give . Adequate Bone Marrow Function Defined : Peripheral absolute neutrophil count ( ANC ) ≥ 750/µL Platelet count ≥ 75,000/µL ( transfusion independent , define receive platelet transfusion within 7day period prior enrollment ) Hemoglobin ≥ 8.0 gm/dL ( may receive RBC transfusion ) Adequate Renal Function Defined : Creatinine clearance radioisotope GFR ≥ 70ml/min/1.73 m2 OR threshold creatinine value base age/gender derive Schwartz formula estimate GFR Adequate Liver Function Defined As : Bilirubin ( sum conjugate + unconjugated ) ≤ 1.5 x upper limit normal ( ULN ) age SGPT ( ALT ) ≤ 5 x upper limit normal ( ULN ) age Serum albumin ≥ 2 g/dL Extraocular retinoblastoma Asynchronous involvement contralateral eye , previously untreated Uncontrolled infection time protocol entry Concomitant Medications : Growth factor support platelet white cell number function must administer within past 3 day Patients currently receive investigational drug , receive investigational drug within last 7 day , ineligible Patients currently receive anticancer agent ineligible Patients opinion investigator may able comply safety monitoring requirement study eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>